These big medtech names performed the best in early 2017

Boston Scientific

[Image courtesy of Boston Scientific]

Boston Scientific: 15%

Boston Scientific has had a busy 1st quarter, investing $45 million in robotic platform maker Corindus Vascular Robotics, putting up $435 million for replacement heart valve developer Symetis and reportedly eyeing a buyout of mitral valve maker Neovasc.
The Marlborough, Mass.–based company has seen share value grow roughly 15% so far in the year, beginning the year at $21.63 and hitting $24.87 on March 31.
The solid share performance comes despite stock values dipping nearly 5% in February after the company announced a voluntary recall of its Lotus transcatheter aortic valve replacement over issues with its locking mechanism.
The company said it reportedly found a “fix” for issues with its Lotus Edge heart valve in January, and is hopeful to file for premarket approval with the FDA some time in May.
How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8

Speak Your Mind